Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

defibrotide sodium

DEFITELIO

defibrotide sodium (DEFITELIO) is a plasminogen activator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 8
Pipeline programs 8
News articles 0
Drug details — defibrotide sodium
US status
approved
Class
—
Route
INTRAVENOUS
Patents
8
Programs
8
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

defibrotide sodium (DEFITELIO) is a plasminogen activator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN defibrotide sodium
Brand DEFITELIO
Mechanism Plasminogen activator
Target Plasminogen
Route INTRAVENOUS
Formulation SOLUTION
Originator Jazz Pharmaceuticals Ireland Limited

Mechanism of action

Plasminogen activator

Primary target: Plasminogen

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Defibrotide Phase 3 · Jazz Pharmaceuticals Ireland · Hepatic Veno-Occlusive Disease
  2. Defibrotide Phase 3 · Jazz Pharmaceuticals Ireland · Veno-occlusive Disease
  3. Defibrotide Phase 3 · Jazz Pharmaceuticals Ireland · Severe Hepatic Veno-Occlusive Disease
  4. Defibrotide Phase 2 · Jazz Pharmaceuticals Ireland · DLBCL
  5. Defibrotide Phase 2 · Jazz Pharmaceuticals Ireland · Transplant-Associated Thrombotic Microangiopathy
  6. Defibrotide Phase 2 · Jazz Pharmaceuticals Ireland · Graft-versus-host Disease
  7. Defibrotide Phase 2 · Jazz Pharmaceuticals Ireland · Covid19
  8. Defibrotide Phase 1 · Jazz Pharmaceuticals Ireland · COVID

Related & competitor drugs

Browse all drugs
  1. aminocaproic acid Tissue-type plasminogen activator inhibitor
  2. tranexamic acid Plasminogen inhibitor
  3. alteplase Tissue-type plasminogen activator exogenous protein
  4. urokinase Urokinase-type plasminogen activator exogenous protein
  5. reteplase Blood and blood forming organs (B01)
  6. tenecteplase Blood and blood forming organs (B01)

Related patents

Browse patents Jazz Pharmaceuticals Ireland Limited patent hub

  1. US 11413264

    Carbamoyl phenylalaninol analogs and uses thereof

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11149000

    Carbamoyl phenylalaninol compounds and uses thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10710958

    Carbamoyl phenylalaninol compounds and uses thereof

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9707270

    Method for administering ω-conopeptide

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9555017

    Methods of making a mixture of salts of gamma-hydroxybutyrate

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8765680

    Method for administering omega-conopeptide

    Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8653033

    Method for administering omega-conopeptide

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8609651

    Pharmaceutical compositions of benzodiazepines and method of use thereof

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is defibrotide sodium?

defibrotide sodium (DEFITELIO) is a plasminogen activator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for defibrotide sodium?

DEFITELIO is a marketed brand name for defibrotide sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of defibrotide sodium?

defibrotide sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.